This Luxembourg Startup Got $1.1M to Hunt for Cures in Space

Jan de Vries · 2026-08-11

What if the next breakthrough cancer treatment didn't come from a lab on Earth, but from a tiny box orbiting hundreds of miles above our heads? That's the bet Exobiosphere is making, and it just got a serious financial boost to prove it. Exobiosphere, a Luxembourg-based space BioTech startup, has secured roughly $1.1 million (€1 million) in non-dilutive funding through Luxembourg's Jeune Entreprise Innovante (JEI) aid scheme. The grant, administered by the country's Ministry of the Economy, will fuel the company's commercial expansion, operations, and the scale-up of its orbital high-throughput screening platform. "This grant lands at exactly the right moment and makes a real difference for a company at our stage," said Kyle Acierno, co-founder and CEO of Exobiosphere. "It allows us to expand our commercial activities, strengthen our team, and bring our technological offer to more pharmaceutical and biotech partners around the world. We're grateful for the continued support of the Luxembourg innovation ecosystem and Ministry of Economy." ### Why Space? Because Gravity Hides Things Here's the core idea that makes Exobiosphere interesting: microgravity accelerates biological processes. Cellular senescence, immune dysregulation, neuronal development, and even tumor aggressiveness all unfold much faster in space than they do on Earth. That means researchers can observe disease mechanisms and drug responses that standard in-vitro models simply can't capture. Think of it like watching a plant grow in fast-forward. You'd notice things you'd miss if you checked once a week. Same principle, but for diseases that normally take years to progress. Founded in 2024 by Acierno alongside Dr. Bruno Santos and Dr. Olivia Borgue, Exobiosphere is building what it describes as the world's first standardized space-based high-throughput testing platform. The goal? Giving pharmaceutical and BioTech companies the ability to run automated experiments in orbit at scale and find what the company calls "cures from space." ### The Tech Behind the Mission The company's core product is the Orbital High-Throughput Screening (OHTS) system. Here's what it can do: - Run more than 2,000 simultaneous automated experiments per mission - Mirror all activity to Earth-based control systems in real time - Feed and differentiate cells autonomously - Dispense toxic compounds or therapeutic drugs without human intervention - Perform plate-reader and microscopy-based readouts It supports applications like complex 3D disease modeling, automated stem cell differentiation, and compound potency testing. Essentially, it's a fully automated lab that happens to be in orbit. ### The Funding Details The JEI scheme is designed for young, research-intensive companies with strong growth potential. It pairs non-dilutive public funding with private investment to help firms move into their next phase of growth. The program co-finances up to 70% of a company's estimated financing needs over as long as three years, capped at about $1.1 million. To qualify, applicants must hold an innovation certificate from Luxinnovation confirming their status as an innovative enterprise. Exobiosphere received this certification ahead of the grant. ### What's Next for Exobiosphere? The capital will accelerate the company's commercial expansion, strengthen internal operations, and grow international business development and marketing activity. It will also support the scale-up of its proprietary orbital high-throughput screening platform. Exobiosphere is currently exploring several therapeutic areas, including oncology, aging, neurodegeneration, radiation response, inflammation, and cardiovascular disease. With this funding in place, the company is positioning itself to bring its orbital lab services to pharmaceutical partners worldwide. For a startup that's barely a year old, landing this kind of support is no small feat. It signals that Luxembourg's innovation ecosystem sees real potential in space-based biomedical research. And honestly, when you think about the drug discovery bottleneck on Earth, maybe the answer really is up there.